Evidence map›Paper›PMID 41530325›Full record

ArticleScientific reports2026

Investigation of the functional hot-spot residues of an enzyme by real-time monitoring of the enzymatic reaction using NMR and computational approaches.

Toshihiko Sugiki, Tomoki Yoshida, Masaki Tsukamoto, Koichiro Miyanishi, Akinori Kagawa, Natsuko Miura, Tomoto Ura, Jun Fukazawa, Yuko Hatanaka, Tsuyoshi Murata and 7 more

Abstract read
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Toshihiko Sugiki *Institute for Protein Research, The University of Osaka, 3-2 Yamadaoka, Suita, Osaka, 565-0871, Japan. sugiki.toshihiko@kitasato-u.ac.jp.
Tomoki Yoshida *Graduate School of Pharmaceutical Science, Kitasato University, 5-9-1 Shirokane, Minato-ku, Tokyo, 108-8641, Japan.
Masaki TsukamotoGraduate School of Informatics, Nagoya University, Furo-cho, Chikusa, Nagoya, Aichi, 464-8601, Japan.
Koichiro MiyanishiGraduate School of Engineering Science, The University of Osaka, 1-3 Machikaneyama, Toyonaka, Osaka, 560-8531, Japan.
Akinori KagawaCenter for Quantum Information and Quantum Biology (QIQB), The University of Osaka, 1-2 Machikaneyama, Toyonaka, Osaka, 560-0043, Japan.
Natsuko MiuraGraduate School of Agriculture, Osaka Metropolitan University, 1-1 Gakuen-cho, Naka-ku, Sakai, Osaka, 599-8531, Japan.
Tomoto UraInstitute for Quantum Life Science, National Institutes for Quantum Science and Technology (QST), 4-9-1 Anagawa, Inage-ku, Chiba, 263-8555, Japan.
Jun FukazawaInstitute for Protein Research, The University of Osaka, 3-2 Yamadaoka, Suita, Osaka, 565-0871, Japan.
Yuko HatanakaCenter for Quantum Information and Quantum Biology (QIQB), The University of Osaka, 1-2 Machikaneyama, Toyonaka, Osaka, 560-0043, Japan.
Tsuyoshi MurataDepartment of Applied Chemistry, Faculty of Engineering, Aichi Institute of Technology, 1247 Yachigusa, Yakusa, Toyota, Aichi, 470-0392, Japan.
Toshimichi FujiwaraInstitute for Protein Research, The University of Osaka, 3-2 Yamadaoka, Suita, Osaka, 565-0871, Japan.
Masahiro KitagawaGraduate School of Engineering Science, The University of Osaka, 1-3 Machikaneyama, Toyonaka, Osaka, 560-8531, Japan.
Yasushi MoritaDepartment of Applied Chemistry, Faculty of Engineering, Aichi Institute of Technology, 1247 Yachigusa, Yakusa, Toyota, Aichi, 470-0392, Japan.
Kumiko Sakai-KatoGraduate School of Pharmaceutical Science, Kitasato University, 5-9-1 Shirokane, Minato-ku, Tokyo, 108-8641, Japan.
Yoichi TakakusagiInstitute for Quantum Life Science, National Institutes for Quantum Science and Technology (QST), 4-9-1 Anagawa, Inage-ku, Chiba, 263-8555, Japan.
Nobutada TanakaGraduate School of Pharmaceutical Science, Kitasato University, 5-9-1 Shirokane, Minato-ku, Tokyo, 108-8641, Japan.
Makoto NegoroCenter for Quantum Information and Quantum Biology (QIQB), The University of Osaka, 1-2 Machikaneyama, Toyonaka, Osaka, 560-0043, Japan.

Funding

Casio Science Promotion Foundation J41-42Core Research for Evolutional Science and Technology JPMJCR1672Frontier Science Support Program by the Institute for Protein Research R1-2Japan Agency for Medical Research and Development JP20am0101072Japan Society for the Promotion of Science JP21K06046Japan Society for the Promotion of Science JP23K05654Ministry of Education, Culture, Sports, Science and Technology JPMXS0120330644
6 · The paper itself

Abstract

Favipiravir is an anti-influenza prodrug that is metabolized to its phosphoribosylated form, favipiravir-ribofuranosyl-5′-monophosphate (favipiravir-RMP), by human endogenous enzyme hypoxanthine-guanine phosphoribosyltransferase (HGPRT). This enzymatic reaction is the rate-determining step in generating the active form of favipiravir, making it important to understand the molecular mechanisms underlying the HGPRT-catalyzed RMP-modification of favipiravir. However, the pharmacokinetics of this reaction have not been fully elucidated, despite X-ray crystallographic studies on the HGPRT-favipiravir complex. Here, we identified functional hot-spot residues in HGPRT that play important roles in the enzymatic conversion of favipiravir to favipiravir-RMP. Real-time monitoring of the HGPRT reaction via ligand-observed solution NMR experiments, biochemical mutagenesis of HGPRT, and computational calculations and molecular dynamics simulations, allowed us to investigate the free binding energetics and structural properties of the interaction between HGPRT and favipiravir-RMP. This powerful hybrid experimental strategy allows the identification of functional hot-spot residues in the enzyme and provide complementary structural biological information. This approach could be universally applicable to investigating drug-protein interaction modes.

Indexed as

AmidesHypoxanthine PhosphoribosyltransferasePyrazinesHumansMagnetic Resonance SpectroscopyMolecular Dynamics SimulationAmidesfavipiravirHypoxanthine PhosphoribosyltransferasePyrazinesAviganFluorine-19HGPRTMolecular dynamics simulationSARS-CoV-2

Identifiers

PMID41530325
PMCPMC12894675

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.